Diffuse alveolar hemorrhage following administration of tirofiban or abciximab: A nemesis of platelet glycoprotein IIb/IIIa inhibitors

Catheterization and Cardiovascular Interventions

Volumn 49, Issue 2, 2000, Pages 181-184

  Ali, Arshad ^a   Patil, Sandish ^a   Grady, Kevin J ^a   Schreiber, Theodore L ^a  

^a ST JOHN HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

Abciximab; Pulmonary hemorrhage; Tirofiban

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; TICLOPIDINE; TIROFIBAN;

AGED; ARTICLE; BRONCHOSCOPY; CASE REPORT; CORONARY ARTERY OBSTRUCTION; CORONARY STENT; ELECTROCARDIOGRAM; ERYTHROCYTE TRANSFUSION; FEMALE; HEART INFARCTION; HUMAN; LUNG HEMORRHAGE; MALE; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; THROMBOCYTE TRANSFUSION; TRANSLUMINAL CORONARY ANGIOPLASTY; UNSTABLE ANGINA PECTORIS;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; FATAL OUTCOME; FEMALE; HEMOPTYSIS; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; MYOCARDIAL ISCHEMIA; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PULMONARY ALVEOLI; THROMBOSIS; TYROSINE;

EID: 0033984901     PISSN: 15221946     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1522-726X(200002)49:2<181::AID-CCD14>3.0.CO;2-J     Document Type: Article

References (15)

1. Braunwald E, Maseri A, Armstrong PW, et al. Rationale and clinical evidence for the use of GP IIb/IIIa inhibitors in acute coronary syndromes. Eur Heart J 1998;19(Suppl D):D22-D30.
2. Coller BS. A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex. J Clin Invest 1985;76:101-108.
3. The EPIC investigators. Prevention of ischemic complications in high-risk angioplasty by a chimeric monoclonal antibody c7E3 Fab fragment directed against the platelet glycoprotein IIb/IIIa receptor. N Engl J Med 1994;330:956-961.
4. Ferguson JJ, Lau TK. New antiplatelet agents for acute coronary syndromes. Am Heart J 1998;135:S194-S200.
5. The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997;96:1445-1453.
6. Ferguson JJ. Meeting highlights: 46th annual scientific sessions of the American College of Cardiology Circulation 1997;96:367-371.
7. Theroux P. Presentation at ESC. Stockholm; 1997.
8. Ferguson JJ, Kereiakes DJ, Adgey AAJ, et al. Safeuse of platelet GP IIb/IIIa inhibitors. Eur Heart J 1998;19(Suppl D):D40-D51.
9. Sitges M, Villa FP. Massive pulmonary hemorrhage in a patient treated with a platelet glycoprotein IIb/IIIa inhibitor. Int J Card 1997;62:269-271.
10. Khanlou H, Tsiodras S, Eiger G, et al. Fatal alveolar hemorrhage and abciximab therapy for acute myocardial infarction. Cathet Cardiovasc Diagn 1998;44:313-316.
11. Khanlou H, Eiger G, Yazdanfar H. Correspondence: abciximab and alveolar hemorrhage. N Engl J Med 1998;339:1861-1862.
12. Cohen SA, Effron MB. Correspondence. N Engl J Med 1998;339: 1862.
13. The EPILOG investigators. Platelet glycoprotein IIb/IIIa receptor and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689-1696.
14. Awadh N, Ronco JJ, Bernstein V, Gilks B, Wilcox P. Spontaneous Pulmonary Hemorrhage after thrombolytic therapy for acute myocardial infarction. Chest 1994;106:1622-1624.
15. Albelda SM, Gefter WB, Epstein DM, Miller WT. Diffuse pulmonary hemorrhage: a review and classification. Radiology 1985; 154(2)289-297.